Bissan Al-Lazikani
Has grant
Professor, Director of Therapeutics Data Science
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Bissan Al-Lazikani serves as the Director of Therapeutics Data Science at The University of Texas MD Anderson Cancer Center in the United States. Her research primarily focuses on the development of innovative algorithms, including those utilizing Structured Query Language and Natural Language Processing, to enhance the identification of lung nodules in a cancer care setting. Professor Al-Lazikani is dedicated to advancing data science applications within oncology to improve patient outcomes.
Recent Grants
Grant: Close
Computational biology and chemogenomics team
Open Date: 2011-10-01
Close Date: 2017-09-30
Grant: Close
Centre for Cancer Therapeutics: Computational Biology and Chemogenomics Team
Open Date: 2009-01-01
Close Date: 2013-12-31
Grant: Close
Chemogenomics.
Open Date: 2008-07-01
Close Date: 2013-01-31
Articles (12)
Dynamic changes in phosphoproteins and EPS. Exemplar of results in a cell line HCC827. A and B, Network diagrams showing phosphoproteomic changes and drug targets with color gradient blue (−1.7) and red (+1.7). Nodes that are drug targets but where phosphorylation has not been measured are denoted in gray, that is, HSP90, PI3K, and BRAF. A, Phosphoproteomic changes related to exposure to the AKT inhibitor capivasertib. B, Phosphoproteomic changes related to exposure to the MEK inhibitor trametinib. C and D, EPS calculated for nodes that are tractable on CanSAR. C, EPS scores upon exposure to the AKT inhibition capivasertib. D, EPS scores upon exposure the MEK inhibitor trametinib.
Year:
2025
Prediction of drug sensitivity using phosphoproteomic analysis. A, Classification of cell line–drug single-agent sensitivities into four quartiles, with Q1 = most sensitive and Q4 = least sensitive. B, Feature importance of phosphoproteins based on elastic net analysis shown. Features are described previously as significant if the weight is greater than +0.1 or lesser than −0.1. C , Performance of predictions of sensitivity quartile based on phosphoproteomic changes using elastic net analysis. D, Performance of prediction of sensitivity quartile based on three clinically relevant mutations ( EGFR , PIK3CA , and KRAS ) using elastic net analysis.
Year:
2025
Comparison phosphoprotein changes in patient samples and cell lines. A, 3D plot showing that for the first three principal components of the phosphoproteomic data, patient samples (blue diamonds) show comparable distribution with cell line data (yellow circles), indicating that changes in phosphorylation in cell line panels could potentially reflect changes within clinical samples. B, Probability density functions of cell line and patient data, showing a strong overlap in distribution and peak values between the two sample types, despite a Welch Two Sample t test, indicating that the two groups have different means ( P = 0.006804). Here, x -axis plots the value of dynamic phosphoprotein changes, and the y -axis (density) is proportional to frequency.
Year:
2025
Acute dynamic phosphoproteomic perturbation. A, Hierarchically clustered heatmap showing 52 phosphoproteomic changes measures across all 35 cell lines exposed to all seven drugs, overlaid with quartiled drug sensitivity annotation, generated using Morpheus. Blue denotes a decreased phosphoprotein, and red denotes an increased phosphoprotein. Drug sensitivity quartiles are as illustrated and discussed in Fig. 3A . Clusters are highlighted with yellow boxes. B, Unrooted dendrogram representing clustering of phosphorylated proteins measured across entire dataset, showing that receptor tyrosine kinases cluster together. Colors represent distinct clusters of the dendrogram, as per slicing at the level annotated by the turquoise line.
Year:
2025
Experimental and predicted combinations. A, Clustered heatmap of Bliss synergy scores was experimentally measured for six cell lines treated with 21 two-drug combinations. B, Histogram representing the EPS rankings of nodes of targets of drugs in the top 25% highest Bliss synergy scores, that is, “most synergistic” (left), or the EPS rankings of nodes of targets of drugs in the 25% lowest Bliss synergy scores, that is, “least synergistic” (right). There is a significant bias toward higher EPS rankings for the most synergistic drug targets, with a significant Mann–Whitney U test P value of 0.0038875, indicating a biased distribution of rankings. C, Simulation of the Mann–Whitney U test P values obtained from 10,000-fold random permutations of EPS ranking, demonstrating the robustness of this P value.
Year:
2025
Experimental design. Single-drug evaluation: A library of 7 targeted anticancer drugs was used. First, GI 50 concentrations were determined in a panel of 35 NSCLC cell lines with diverse genetic backgrounds ( 44 ). Second, phosphoproteomic changes of 52 selected proteins were measured after 1 hour of drug exposure of the drugs at clinically relevant concentrations adjusted for protein binding and DMSO controls were measured. The phosphoproteomic protein changes were used to train machine learning predictors of sensitivity, and validated using 100-fold cross validation with a rotating set of 15% leave out for validation and 85% for training (see Materials and Methods). The same phosphoproteomic measurements were also carried out in 16 patient samples obtained from pleural effusions producing profiles that can be fed into the predictive model to predict likely response to each drug of the individual patient samples. Two-drug combination: A novel machine learning method (environmental perturbation score) using dynamic phosphoprotein data 35 cell lines exposed to the 7 drugs was used to predict combinations. All pair wise two-drug combinations (7 individual drugs) were tested in 6 representative NSCLC cell lines and Bliss synergy was calculated for all combinations. The predicted results from the environmental perturbation score was compared with the experimentally validated results.
Year:
2025
We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed and progressive solid tumors of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intratumor heterogeneity captured by the latter, if sufficient ctDNA was present. Serial tumor sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature. In keeping with epigenetic alterations being a common driver of many childhood cancers, fragmentomic analysis of cfDNA identified tumor-specific epigenetic states and transcription factor binding sites accessible in chromatin. This study leverages a large and well-annotated genomic dataset of aggressive childhood malignancies, identifies genomic and epigenetic drivers of childhood cancer relapse, and highlights the power and practicality of cfDNA analysis to capture both intratumoral heterogeneity and the epigenetic state of cancer cells. Significance: In tumors of childhood, we identify mutations in epigenetic genes as drivers of relapse, with matched cfDNA sequencing showing significant intratumor genetic heterogeneity and cell-state specific patterns of chromatin accessibility. This highlights the power of cfDNA analysis to identify both genetic and epigenetic drivers of aggressive disease in pediatric cancers.
Year:
2025
We hypothesize that the study of acute protein perturbation in signal transduction by targeted anticancer drugs can predict drug sensitivity of these agents used as single agents and rational combination therapy. We assayed dynamic changes in 52 phosphoproteins caused by an acute exposure (1 hour) to clinically relevant concentrations of seven targeted anticancer drugs in 35 non–small cell lung cancer (NSCLC) cell lines and 16 samples of NSCLC cells isolated from pleural effusions. We studied drug sensitivities across 35 cell lines and synergy of combinations of all drugs in six cell lines (252 combinations). We developed orthogonal machine-learning approaches to predict drug response and rational combination therapy. Our methods predicted the most and least sensitive quartiles of drug sensitivity with an AUC of 0.79 and 0.78, respectively, whereas predictions based on mutations in three genes commonly known to predict response to the drug studied, for example, EGFR , PIK3CA , and KRAS , did not predict sensitivity (AUC of 0.5 across all quartiles). The machine-learning predictions of combinations that were compared with experimentally generated data showed a bias to the highest quartile of Bliss synergy scores ( P = 0.0243). We confirmed feasibility of running such assays on 16 patient samples of freshly isolated NSCLC cells from pleural effusions. We have provided proof of concept for novel methods of using acute ex vivo exposure of cancer cells to targeted anticancer drugs to predict response as single agents or combinations. These approaches could complement current approaches using gene mutations/amplifications/rearrangements as biomarkers and demonstrate the utility of proteomics data to inform treatment selection in the clinic.
Year:
2025
canSAR (https://cansar.ai) continues to serve as the largest publicly available platform for cancer-focused drug discovery and translational research. It integrates multidisciplinary data from disparate and otherwise siloed public data sources as well as data curated uniquely for canSAR. In addition, canSAR deploys a suite of curation and standardization tools together with AI algorithms to generate new knowledge from these integrated data to inform hypothesis generation. Here we report the latest updates to canSAR. As well as increasing available data, we provide enhancements to our algorithms to improve the offering to the user. Notably, our enhancements include a revised ligandability classifier leveraging Positive Unlabeled Learning that finds twice as many ligandable opportunities across the pocketome, and our revised chemical standardization pipeline and hierarchy better enables the aggregation of structurally related molecular records.
Year:
2024
Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR that drives transcriptional activity in CRPC remains a challenging therapeutic target. Herein we demonstrate that BCL-2–associated athanogene-1 (BAG-1) mRNA is highly expressed and associates with signaling pathways, including AR signaling, that are implicated in the development and progression of CRPC. In addition, interrogation of geometric and physiochemical properties of the BAG domain of BAG-1 isoforms identifies it to be a tractable but challenging drug target. Furthermore, through BAG-1 isoform mouse knockout studies, we confirm that BAG-1 isoforms regulate hormone physiology and that therapies targeting the BAG domain will be associated with limited “on-target” toxicity. Importantly, the postulated inhibitor of BAG-1 isoforms, Thio-2, suppressed AR signaling and other important pathways implicated in the development and progression of CRPC to reduce the growth of treatment-resistant prostate cancer cell lines and patient-derived models. However, the mechanism by which Thio-2 elicits the observed phenotype needs further elucidation as the genomic abrogation of BAG-1 isoforms was unable to recapitulate the Thio-2–mediated phenotype. Overall, these data support the interrogation of related compounds with improved drug-like properties as a novel therapeutic approach in CRPC, and further highlight the clinical potential of treatments that block persistent AR signaling which are currently undergoing clinical evaluation in CRPC.
Year:
2024
Year:
2024
Year:
2021
Collaborators (32)
Sanjay Popat
Reader
Institute of Cancer Research
Udai Banerji
Co-Director DDU and Professor of Molecular Cancer Pharmacology
The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Ines Figueiredo
Institute of Cancer Research
Michael Hubank
Professor of Translational Genomics
University College London
Juliet Gray
Professor of Paediatric Oncology
University of Southampton
Adam Sharp
Team Leader
Institute of Cancer Research
Chris Jones
Professor of Childhood Brain Tumour Biology
Institute of Cancer Research
Steven C. Clifford
Prof of Molecular Paediatric Oncology
Newcastle University
Paul Workman
Harrap Professor of Pharmacology & Therapeutics
Institute of Cancer Research
Susanne Andrea Gatz
University of Birmingham
Nicole Jung
Karlsruhe Institute of Technology
Stephen R. Plymate
University of Washington
William Anderson
University College London
Guy Makin
Senior Lecturer in Paediatric Oncology
The University of Manchester
Trevor A Graham
Director
Institute of Cancer Research
Johann S de Bono
Head of Clinical Studies Division
Institute of Cancer Research
Janet Shipley
Group Leader, Sarcoma Molecular Pathology
Institute of Cancer Research
Stefan Braese
Director
Karlsruhe Institute of Technology
Deborah A. Tweddle
-
Ridwan Shaikh
Institute of Cancer Research
Xavier Salvatella
Group Leader
ICREA
Sally George
Institute of Cancer Research
Myles Brown
Emil Frei III Professor of Medicine
Dana-Farber Cancer Institute
Richard Grundy
Professor of Paediatric Neuro-Oncology and Cancer Biology
University of Nottingham
Louis Chesler
professor
Institute of Cancer Research
Amos Burke
Professor of Paediatric Oncology and Director
University of Birmingham
Isidro Cortes Ciriano
Research Group Leader
European Bioinformatics Institute
Andrea Sottoriva
Head
Human Technopole
Borja Mateos
Assistant Professor
University of Barcelona
Darren Hargrave
University College London
Carolin Sauer
Group Leader
Vall d'Hebron Institute of Oncology
Pamela Kearns
University of Birmingham
Make your next move.
Prepare your application
Review drafts before you send them.